AstraZeneca scraps three early-stage programs, US COVID-19 vaccine effortsBusiness, R&D, TherapeuticsAstraZeneca will give up on seeking approval for its COVID-19 vaccine in the United States, the company announced during its third-quarter report. It is also abandoning three early-stage programs. Read more November 10, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/04/BioSpaceAstraZenecaflags4282022.jpg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-11-10 10:31:212022-11-10 11:39:10AstraZeneca scraps three early-stage programs, US COVID-19 vaccine efforts